Satori brings in $22M to stop Alzheimer’s in its tracks
Satori Pharmaceuticals, a company that says it’s developing drugs with the potential to actually stop Alzheimer’s disease in its early phases — an unprecedented claim — landed $22 million in second-round funding to push its products through a first battery of tests.
Based in Cambridge, Mass., the firm has broken away from the usual drugs, like Pfizer’s Aricept, that slow the symptoms but don’t address the base-level process of the disease. Most of these treatments have… Continue Reading